Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS
Study data from A.K. Dudani et al provide new insights into HIV/AIDS
July 30th, 2008
"A current urgent priority is to develop microbicides and vaccines to combat retroviruses like human immunodeficiency virus ( HIV). We show that the cysteine-selective natural compound, taurine chloramine (T-NCl), can be effective in this task," researchers in Ottawa, Canada report. "A number of proteins in all retroviruses contain highly conserved cysteine-rich regions that are essential for infection and replication. Our data show that by targeting these essential cysteine residues, T-NCl ( 2 or 5 mM) acts as a highly effective and safe microbicide that fully blocks the infectivity of high HIV-1 titers (10(6) TCID50 units/ ml) but is not injurious to eukaryotic cells....
Source: Vaccine Weekly (2008-07-30)
|
